Analysis examines the impact of insurance changes on long-acting cabotegravir plus rilpivirine delivery, indicating potential treatment delays.
Long-acting injectable cabotegravir plus rilpivirine offers an alternative to daily oral antiretroviral therapy, but insurance-related barriers can disrupt implementation. We examined the frequency and impact of insurance changes in a United States cohort and found that nearly half of patients experienced insurance changes, which could lead to delayed injections.
No takes yet. Share an insight, caveat, or question.
Davis et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: